Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
scarring
Biotech
Promore's phase 2 scar trial fail sends stock spiraling down
The nine-year wait for new clinical data ended in disaster, with the failure of the polypeptide to reduce scarring wounding the biotech’s share price.
Nick Paul Taylor
Apr 20, 2023 7:15am
Acelyrin snags $250M, licenses Affibody IL-17 asset for 3 trials
Nov 16, 2021 5:00am
'Safety concerns' see Biogen ax phase 2 study of fibrosis med
Sep 17, 2019 2:56am
AzurRx’s chronic pancreatitis drug hits the mark in phase 2
Sep 24, 2018 4:53pm
Early trial shows application of RXi’s skin-scar drug in wet AMD
Aug 1, 2018 2:42pm
Regenerating hair follicles could be key in reducing scar tissue
Jan 5, 2017 2:01pm